Using CRISPR gene editing, a team from Children’s Hospital of Philadelphia (CHOP) and Penn Medicine have thwarted a lethal lung disease in an animal model in which a harmful mutation causes death within hours after birth.
This proof-of-concept study, published today in Science Translational Medicine, showed that in uteroediting could be a promising new approach for treating lung diseases before birth.
“The developing fetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, MD, an investigator at CHOP’s Center for Fetal Research, and a pediatric and fetal surgeon in CHOP’s Center for Fetal Diagnosis and Treatment. “Furthermore, the ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting. This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”
The lung conditions the team is hoping to solve — congenital diseases such as surfactant protein deficiency, cystic fibrosis, and alpha-1 antitrypsin — are characterized by respiratory failure at birth or chronic lung disease with few options for therapies. About 22 percent of all pediatric hospital admissions are because of respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes. Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.
“We wanted to know if this could work at all,” said study co-leader Edward E. Morrisey, PhD, a professor of Cardiovascular Medicine in the Perelman School of Medicine at the University of Pennsylvania. “The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”
The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during fetal development resulted in targeted changes in the lungs of mice. They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.
The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways. In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells. These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly, but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.
In a second experiment, the researchers used prenatal gene editing to reduce the severity of an interstitial lung disease, surfactant protein C (SFTPC) deficiency, in a mouse model that has a common disease-causing mutation found in the human SFTPC gene. One hundred percent of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22 percent of the animals.
Future studies will be directed toward increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs. “Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.
The Latest on: Gene editing
via Google News
The Latest on: Gene editing
- Gene Editing Tools Market is expected to grow at an approximate CAGR of 18% over 2019-2029on January 26, 2021 at 2:28 am
Market players are extending their product portfolios and are making investments to fulfill the research requirements. FMI in its recent study on the ...
- Gene Editing Technology Market Size : Technological Advancement and Growth Analysis with Forecast to 2026on January 25, 2021 at 9:46 am
Jan (Market Insight Reports) -- Market Study Report, LLC’s latest addition on ‘ Gene Editing Technology market’ is a research that ...
- Spotting Every Needle in the Haystack: CRISPeR Gene Editing for DNA with Lone Mutationson January 25, 2021 at 5:36 am
The quest to change the very nature of being, has driven philosophical and metaphysical debates for ages. Now, with the advent of ...
- Killing cancer by stealth: Gene editing firm Precision Bio secures another FDA approval to advance drugson January 22, 2021 at 12:10 pm
The Durham clinical-stage biotechnology company has received U.S. Food and Drug Administration approval to advance its new drug for patients with relapsed/refractory non-Hodgkin Lymphoma.
- Gene Editing Technique Halts Premature Aging In Miceon January 21, 2021 at 12:41 pm
A specialized gene editing technique that allows very small and precise changes to be made to the genetic code can halt a disease that causes premature aging in a mouse model and double the lifespan ...
- Temple spinoff Express Cells secures first patent for gene-editing technologyon January 20, 2021 at 6:19 pm
A three-year-old Philadelphia genetic engineering company spun out of Temple University has secured its first patent for its core gene-editing technology. ExpressCells was awarded the U.S. patent for ...
- Gene editing shows potential to correct mutations causing inherited retinal degenerationon January 20, 2021 at 5:11 am
Gene editing therapies, including CRISPR-Cas systems, offer the potential to correct mutations causing inherited retinal degenerations, a leading cause of blindness.
- Gene Editing for Hogs Just Around the Corneron January 19, 2021 at 11:33 am
From Washington DC to farm fields throughout much of the country, the acronym ESG has become a rather hot-button issue of late.
- Gene-editing 'scissor' tool may also be a 'dimmer switch'on January 19, 2021 at 6:03 am
In a series of experiments with laboratory-cultured bacteria, Johns Hopkins scientists have found evidence that there is a second role for the widely used gene-cutting system CRISPR-Cas9 -- as a genet ...
- France backs non-GMO regulation for crop gene-editing in EUon January 18, 2021 at 3:17 pm
France sees crops developed using gene-editing techniques as different to genetically modified organisms (GMOs) and opposes a European Union court decision to put them under strict GMO regulations, ...
via Bing News